U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07610720) titled 'Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer' on May 06.
Brief Summary: Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Advanced/Metastatic Breast Cancer
HER2-Positive Metastatic Breast Cancer
Intervention:
DRUG: Dalpiciclib
Oral CDK4/6 inhibitor (dose modification permitted for toxicity management)
DRUG:...